Sulfated CCK-8s and Anxiety-Like Behavior in Zebrafish: Mechanistic Insights from Central Administration Studies

Study Background and Research Question

Cholecystokinin (CCK) is a multifunctional brain–gut peptide, recognized for its influence on satiety, pain, and emotional responses across vertebrates. The C-terminal octapeptide variant, particularly in its sulfated form (CCK-8s), is prominent in both the central and peripheral nervous systems, mediating its effects primarily through two G protein-coupled receptors: CCKA (CCK1R) and CCKB (CCK2R). While CCK-8s has been extensively studied in mammalian systems—where it impacts feeding, anxiety, and nociception—the neurobehavioral actions of CCK-8s in non-mammalian models remain poorly defined. Zebrafish (Danio rerio), with their transparent brains and robust behavioral paradigms, offer a unique opportunity to systematically dissect the psychophysiological actions of neuropeptides like CCK-8s. The reference study posed a key question: Do centrally administered sulfated CCK-8s isoforms modulate anxiety-like behavior in zebrafish, and through which neural circuits?

Key Innovation from the Reference Study

The principal innovation of the research lies in its direct demonstration that intracerebroventricular (ICV) administration of two endogenous molecular forms of zebrafish CCK-8s (zfCCKA-8s and zfCCKB-8s) robustly induces anxiety-like behavior in vivo. This provides the first functional evidence that both CCK1R and CCK2R-linked signaling pathways are operative in the zebrafish brain, and that the anxiogenic role of CCK-8s is evolutionarily conserved. By mapping CCK-like immunoreactivity and comparing behavioral outcomes to established anxiogenic agents, the study bridges a critical knowledge gap in comparative neuropeptide research (reference study).

Methods and Experimental Design Insights

The study utilized a rigorous experimental approach combining neuroanatomical mapping and behavioral pharmacology. Zebrafish brains were first immunostained to localize CCK-like peptides, revealing broad distribution, with pronounced signals in the ventral habenular, interpeduncular, and superior raphe nuclei—regions implicated in emotional regulation. Behavioral assays involved ICV injections of synthetic zfCCKA-8s and zfCCKB-8s at doses of 1, 5, and 10 pmol/g body weight. Anxiety-like behavior was quantitatively assessed using the 'novel tank diving test,' which measures the time spent in upper versus lower tank zones—a validated metric in zebrafish research. The study included both positive (FG-7142, a benzodiazepine receptor inverse agonist) and negative (vehicle) controls, and further tested the specificity of the response by co-administering the CCK receptor antagonist proglumide.

Protocol Parameters

• ICV administration of CCK-8s: 1, 5, or 10 pmol/g body weight; behavioral observation commenced immediately post-injection.
• Receptor antagonist validation: Proglumide at 200 pmol/g body weight was co-administered to confirm CCK receptor pathway involvement.
• Behavioral readout: Preference test (novel tank), with anxiety-like behavior defined by reduced time in the upper tank zone.
• Control agents: FG-7142 (anxiogenic comparator) at 10 pmol/g body weight.

Core Findings and Why They Matter

Both zfCCKA-8s and zfCCKB-8s, when centrally administered at 10 pmol/g body weight, significantly reduced the time zebrafish spent in the upper tank region, mirroring the effect of the anxiogenic control FG-7142. This behavioral shift indicates a robust anxiety-like phenotype. Importantly, the anxiogenic actions of both molecular forms were fully attenuated by proglumide, confirming mediation via CCK receptor signaling. These results suggest that the central CCK system modulates emotional states in zebrafish, paralleling mammalian findings, and that both CCK1R and CCK2R pathways are functionally relevant in this species (reference study).

This study thus advances the zebrafish model as a tractable system for dissecting neuropeptide-driven modulation of affective states. The demonstration of context- and concentration-dependent behavioral effects provides a platform for translational research into the molecular basis of anxiety disorders and the screening of neuroactive compounds.

Comparison with Existing Internal Articles

The present findings align with and extend observations reported in internal reviews. For instance, the article "Cholecystokinin Octapeptide Ammonium: Mechanistic Insights and Translational Impact" discusses the context-specific actions of CCK-8 ammonium on neurobehavioral outcomes, highlighting its dual roles in anxiolytic and anxiogenic signaling depending on receptor subtype and experimental paradigm. The detailed behavioral pharmacology in zebrafish complements earlier mammalian and cell-based insights described in "Applied Workflows with Cholecystokinin Octapeptide Ammonium", which emphasizes the peptide's capacity for precise neurobehavioral and apoptosis modulation.

Moreover, the internal summary "Sulfated CCK-8 Induces Anxiety-Like Behavior in Zebrafish" corroborates the reference study's primary findings, underscoring the zebrafish as a model for investigating anxiety-like behavior induction by neuropeptides.

Limitations and Transferability

While the study robustly demonstrates that both zfCCKA-8s and zfCCKB-8s trigger anxiety-like behaviors via central CCK receptor signaling, several limitations warrant consideration. The ICV administration route, though effective for mechanistic probing, is invasive and not representative of physiological peptide release patterns. Additionally, the behavioral assays, while well-validated in zebrafish, capture only one dimension of anxiety-like states and may not fully extrapolate to complex affective behaviors in mammals. Dose–response relationships were explored within a narrow range (1–10 pmol/g), and receptor subtype-specific contributions could be further dissected with selective agonists/antagonists. Despite these caveats, the evolutionary conservation of CCK receptor pathways and behavioral outcomes supports a degree of cross-species transferability for neuropeptide research, with zebrafish providing a scalable and genetically tractable platform.

Research Support Resources

For researchers seeking to replicate or extend these findings, ready access to standardized CCK-8 reagents is essential. Cholecystokinin octapeptide ammonium (SKU C8717) is available in a well-characterized, sulfated form suitable for in vitro and in vivo studies of CCK1R/CCK2R-mediated signaling, including inhibition of apoptosis in neuronal cells, modulation of immune responses, and behavioral assays such as anxiety-like behavior induction in zebrafish. The product information specifies effective experimental concentrations and storage requirements, facilitating reproducible neurobiological and immunological workflows. For protocol optimization and troubleshooting in behavioral or cell-based models, consult recent workflow articles and product guidance from APExBIO.